• Skip to main content
BC

biochimica clinica

en_US English
en_US English it_IT Italian
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

RASSEGNE - Reviews

Volume:

Biochimica Clinica 2019; 43(4) 357-365

Pubblicato on-line:

September 5, 2019

DOI:

10.19186/BC_2019.051

Scarica in PDF:
Autenticazione richiesta

Identificazione di geni di normalizzazione per studi trascrizionali con Polymerase Chain Reaction

AUTORI

Alice Nevone1, Pasquale Cascino1, Margherita Bozzola1, Giovanni Palladini1, Mario Nuvolone1
1Centro per lo Studio e la Cura delle Amiloidosi Sistemiche, Laboratorio di Biochimica Biotecnologie e Diagnostica Avanzata, Fondazione IRCCS Policlinico San Matteo, Dipartimento di Medicina Molecolare, Università di Pavia

ABSTRACT

Identification of genes for normalization of RT-qPCR gene expression data: a review of published literature

Reverse-transcriptase quantitative Polymerase Chain Reaction (RT-qPCR) is a well-established technique to quantify gene expression levels and critically depends on reference genes for data normalization.
We performed a review of biomedical literature to analyse the usage of RT-qPCR in relation to other techniques for transcriptional analyses and to describe practices for the identification of suitable reference genes for RT-qPCR.
In the 81 analysed studies, 3 genes (GAPD, ACTB, B2M) were included in ≥70% of cases, but ranked among the most stable genes in ≤1/3 of cases. The most frequently used normalizing algorithm was geNorm(83%), followed by NormFinder(73%) and BestKeeper(32%).
We also analysed transparency and good laboratory practices based on adherence to the Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines, using selected validated evaluation criteria. Overall, key MIQE criteria were satisfied in ≥50% of analyzed studies, but only four criteria (details of employed kit/enzyme for reverse transcription, priming method, primers/probes and DNA polymerase) were satisfied in ≥90% of cases. Data on assay repeatability were reported only in 15% of studies. The presence of pseudogenes as a potential confounder of assay specificity was evaluated only in 13% of studies. Finally, as few as 6% of studies accounted for the presence of known mutations of singly nucleotide polymorphisms when designing assay primers/probes.
Better adherence to the MIQE guidelines should be encouraged. Publicly available transcriptomic and genomic data sets could be employed to refine the identification of suitable normalizing genes and to assist assay design.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967